Key StatisticsRegeneron Pharmaceuticals, Inc. (REGN) declined -0.96% and closed its last trading session at $402.62. Its opening price on the last trading day was $406.52. The company’s market cap is $43.86 Billion. The company has 108.94 Million shares outstanding and 79.18 Million shares were floated in market. The short ratio in the company’s stock is documented at 3.15 and the short float is around of 3.05%. Regeneron Pharmaceuticals, Inc. has been given an analysts’ mean target of 496.3.52-week High/LowThe highest price REGN stock touched in the last 12 month was $543.55 and the lowest price it hit in the same period was $325.35. Stock’s distance from 52 week High is -25.93% and the distance from 52 week Low is 23.75%.Share Volume AnalysisA total of 1.03 Billion shares exchanged at hands and its average trading volume is standing at 766.99 Million shares. The relative volume of the stock is 1.34.Stock PerformanceRegeneron Pharmaceuticals, Inc. (REGN) performance during the last one year upgraded 16.69 percent, while its year to date (YTD) performance showed a positive trend of 9.68 percent. The stock fell -1.08 percent over the past six months. The stock’s quarterly performance indicates a negative momentum of -15.56 percent, whereas its last one month trend is pessimistic with -12.9 percent. Its weekly performance showed downward trend of -5.6 percent.Profit Margins AnalysisProfitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at 22.1 percent, operating profit margin was 32.3 percent, while gross profit margin stands at 55.2 percent.Key Ratios ReviewLiquidity ratios help investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 3.4, current ratio was 3.8, LT Debt/Equity ratio was 0.13 and Total Debt/Equity ratio stands at 0.13, while Payout ratio is 0.Return on Assets, Investment and EquityRegeneron Pharmaceuticals, Inc. (REGN) has a Return on Assets of 15.5 percent, Return on Investment of 18.2 percent and a Return on Equity of 23.9 percent.Simple Moving AverageMoving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also helps in determining where it may be possibly heading. Now we look at the Moving Averages, the 200-day is -6.9%, the 50-day is -11.05% and the 20-day is -8.84%.EPS Growth AnalysisThe company’s diluted EPS for trailing twelve months was 9.96.EPS Estimate for the next year is 16.36.EPS Estimate for the next Quarter is 3.85.EPS Growth this year is 39.5 percent.Earnings and Sales GrowthEPS growth for the next 5 years is 17.96 percent.Annual EPS growth Past 5 years is 38.8 percent.Annual Sales Growth in the past 5 years was 61.3 percent.Quarterly Revenue Growth on year-over-year basis stands at 21.2 percent.Quarterly Earnings Growth on year-over-year basis stands at 97.8 percent.Investment Valuation RatiosThe company P/E (price to earnings) ratio is 40.42 and Forward P/E ratio is 24.6. The company P/S (price to Sales) ratio is 8.38, P/B (price to Book) ratio is 7.73, while its P/C (price to Cash) ratio stands at 34.6.Volatility AnalysisIf we look at the Volatility of Regeneron Pharmaceuticals, Inc. (REGN), Week Volatility is 2.39%, whereas Month Volatility is at 2.32%.Technical IndicatorsRegeneron Pharmaceuticals, Inc. (REGN)’s RSI (Relative strength index) is at 20.68, its ATR (Average True Range) value is 10.31, while its Beta factor was calculated at 1.58.Earnings Released DateThe company last reported its quarterly results on Nov 08 BMO.Analysts RecommendationRegeneron Pharmaceuticals, Inc. (REGN) has an Analysts’ Mean Recommendation of 2.3.Insider Ownership and TransactionsRegeneron Pharmaceuticals, Inc.’s insider ownership stands at 0.4 percent, while its insider transaction is -24.23 percent.Institutional Ownership and TransactionsInstitutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. Regeneron Pharmaceuticals, Inc.’s institutional ownership is 71.9%, while its institutional transactions stand at 0.16%.